bluuebunny/crossref_metadata_2025_split huggingface dataset:
Castleman disease of plasma cell type accompanied with bronchiolitis obliterans: a case report and review of the literature
Authors: Zhu Qingyuan , Wang Shuiyou 
Published: December 2023

Abstract
Background
Castleman disease, also known as giant lymph node hyperplasia or angiofollicular lymph node hyperplasia, is a highly heterogeneous clinicopathological entity that belongs to the family lymphoproliferative disorders. Castleman disease accompanied by bronchiolitis obliterans is uncommon and often poses a great diagnostic challenge, which is easily confused with respiratory diseases and impeding the correct diagnosis and treatment. The main aim in presenting such rare case studies is to raise awareness and expand the diagnostic horizon of clinicians for appropriate management.

Case presentation
Here, we present a 69-year-old Chinese male who was admitted to our hospital due to right chest pain for 6 months, accompanied by cough, expectoration, and fever. Laboratory examinations revealed elevated immunoglobulin G and C-reactive protein, and normal serum levels of tumor markers and interleukin-6. Computed tomography scan detected diffuse bronchial wall thickening and patchy area of air trapping consistent with small airway disease. Pulmonary function test showed mild small airway obstructive ventilation dysfunction and moderate decrease in diffusion capacity. The pathological result of the right axillary lymph node was consistent with the plasma cell type Castleman disease. According to the above examinations, the patient was finally diagnosed with the plasma cell type Castleman disease accompanied with bronchiolitis obliterans. He received immunosuppressive medication after surgery and has been followed up for 11 months. Now the patient is currently in stable condition without recurrence.

Conclusion
Castleman disease is a rare lymphoproliferative disorder with a variety of symptoms. At present, the treatment of Castleman disease accompanied with bronchiolitis obliterans is mostly based on experiences or previous case reports, and there is no standard treatment. Here, we report an uncommon case of Castleman disease accompanied with bronchiolitis obliterans in which the patient received immunosuppressive medication after surgery and has been followed up for 11 months without experiencing a recurrence, which may deepen and extend our understanding of this disease.
Establishing performance standards for child development: learnings from the ECDI2030
Authors: Petrowski Nicole , de Castro Filipa , Davis-Becker Susan , Gladstone Melissa , Lindgren Alves Claudia Regina , Becher Yvonne , Grisham Jennifer , Donald Kirsten , van den Heuvel Meta , Kandawasvika Gwendoline , Maqbool Shazia , Tofail Fahmida , Xin Tao , Zeinoun Pia , Cappa Claudia 
Published: December 2023

Abstract
Background
Standards of early childhood development (ECD) are needed to determine whether children living in different contexts are developmentally on track. The Early Childhood Development Index 2030 (ECDI2030) is a population-level measure intended to be used in household surveys to collect globally comparable data on one of the indicators chosen to monitor progress toward target 4.2 of the Sustainable Development Goals: The proportion of children aged 24–59 months who are developmentally on track in health, learning and psychosocial well-being.

Methods
To define performance cut-scores for the ECDI2030 we followed a criterion-referenced standard setting exercise using the modified Angoff method. The exercise gauged the expectations from 15 global experts in ECD and was informed by representative population data collected in Mexico and the State of Palestine. The final calibrated age-specific performance cut-scores were applied to these data to estimate the proportion of children developmentally on track, disaggregated by background characteristics, including the child's sex and attendance to early childhood education.

Results
Through a process of standard setting, we generated robust performance standards for the ECDI2030 by establishing five age-specific cut-scores to identify children as developmentally on track.

Conclusions
This paper demonstrated how the standard setting methodology, typically applied to measures in the health and education fields, could be applied to a measure of child development. By creating robust criterion-referenced standards, we have been able to ensure that the cut-scores related to age for the ECDI2030 are based on performance standards set by global experts in the ECD field for defining on and off track development.
Antenatal care management platform
Authors: Aliyi Abdulmalik , Mesfin Bruk , Hassen Fuad , Dejene Gemechu , Wondimu Hawi , Yizengaw Mignot , Dereje Derartu , Dawud Ahmed Ali 
Published: December 2023

Abstract
Background
Pregnancy is a process of developing a fetus in a woman’s womb leading to anatomical and physiological changes. Currently, numerous health facilities offering antenatal services are yet to adopt health informatics. This led to several challenges, including unskilled, early and poor quality antenatal and delivery care, case traffic because many patients are admitted per day, and shy medical professional doctors, nurses, midwives and nursing aids. The main idea of this project was to design and develop a new system for managing maternal health in antenatal care.

Methods
This web-based antenatal care management platform is designed using XAMPP, PHP, HTML and CSS. It involves designing the stoner interface and identifying the inputs, outputs, and processes of the designed system. The configuration involves the use of case diagrams, sequence diagrams and class diagram tools to achieve the physical consummation of the antenatal care management platform and positive living information system. The purpose of this work was to create a web-based platform for managing antenatal care.

Results
The designed project was tested by using parameters such as WHO guidelines, security, user-friendliness and data storage. Three testing criteria, namely, unit testing, integration testing and system testing, were used to check the efficiency and effectiveness of the antenatal care management platform (ANCMP). The platform that was created met almost all of the criteria that were set out in the design.

Conclusion
This project is objectively targeted to develop a web-based antenatal care management system to overcome the complications that occur during and following gestation.
It controls the overall conditioning of antenatal care, which includes the enrollment of expectant mothers, shadowing of the listed day and reminding them via email and effectively recording and saving all medical information about the mothers.
Prior Authorization and Association With Delayed or Discontinued Prescription Fills
Authors: Kyle Michael Anne , Keating Nancy L. 
Published: December 2023

PURPOSE Prior authorization requirements are increasing but little is known about their effects on access to care. We examined the association of a new prior authorization policy with delayed or discontinued prescription fills for oral anticancer drugs among Medicare Part D beneficiaries. METHODS Using Medicare part D claims data from 2010 to 2020, we studied beneficiaries regularly filling one of 11 oral anticancer drugs, defined as three 30-day fills in 120 days preceding the plan's prior authorization policy change on that drug and continuously enrolled in the same plan for 120 days before and after the policy change at the start of a new year. The control group consisted of beneficiaries meeting the same utilization criteria, but who were enrolled in plans at the same time that did not implement a prior authorization policy change. The outcomes of interest were discontinuation of the drug within 120 days (analyzed with regression analyses) and time (in days) to next fill after a prior authorization policy change (analyzed using a quasi-experimental difference-in-differences event study). RESULTS The introduction of a new prior authorization on an established drug increased the odds of discontinuation within 120 days (adjusted odds ratio, 7.1 [95% CI, 6.0 to 8.5]; P < .001) and increased time to next fill by 9.7 days (95% CI, 8.2 to 11.2; P < .001), relative to patients whose plans did not have a prior authorization policy change. CONCLUSION Introduction of a new prior authorization policy on an established drug regimen is associated with increased probability of discontinued and delayed care. For some conditions, this may represent a clinically consequential barrier to access. Waiving prior authorization for patients already established on a drug may improve adherence.
Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations
Authors: Peters Mary Linton B. , Eckel Andrew , Seguin Claudia L. , Davidi Barak , Howard David H. , Knudsen Amy B. , Pandharipande Pari V. 
Published: December 2023

PURPOSE We evaluated the potential cost-effectiveness of combined magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) screening for pancreatic ductal adenocarcinoma (PDAC) among populations at high risk for the disease. METHODS We used a microsimulation model of the natural history of PDAC to estimate the lifetime health benefits, costs, and cost-effectiveness of PDAC screening among populations with specific genetic risk factors for PDAC, including BRCA1 and BRCA2, PALB2, ATM, Lynch syndrome, TP53, CDKN2A, and STK11. For each high-risk population, we simulated 29 screening strategies, defined by starting age and frequency. Screening included MRI with follow-up EUS in a subset of patients. Costs of tests were based on Medicare reimbursement for MRI, EUS, fine-needle aspiration biopsy, and pancreatectomy. Cancer-related cost by stage of disease and phase of treatment was based on the literature. For each high-risk population, we performed an incremental cost-effectiveness analysis, assuming a willingness-to-pay (WTP) threshold of $100,000 US dollars (USD) per quality-adjusted life year (QALY) gained. RESULTS For men with relative risk (RR) 12.33 ( CDKN2A) and RR 28 ( STK11), annual screening was cost-effective, starting at age 55 and 40 years, respectively. For women, screening was only cost-effective for those with RR 28 ( STK11), with annual screening starting at age 45 years. CONCLUSION Combined MRI/EUS screening may be a cost-effective approach for the highest-risk populations (among mutations considered, those with RR >12). However, for those with moderate risk (RR, 5-12), screening would only be cost-effective at higher WTP thresholds (eg, $200K USD/QALY) or with once-only screening.
Skull Base Tumors
Authors: Forst Deborah A. , Jones Pamela S. 
Published: December 2023

ABSTRACT

Objective
This article reviews the presenting features, molecular characteristics, diagnosis, and management of selected skull base tumors, including meningiomas, vestibular schwannomas, pituitary neuroendocrine tumors, craniopharyngiomas, chordomas, ecchordosis physaliphora, chondrosarcomas, esthesioneuroblastomas, and paragangliomas.

Latest Developments
Skull base tumors pose a management challenge given their complex location and, as a result, the tumors and treatment can result in significant morbidity. In most cases, surgery, radiation therapy, or both yield high rates of disease control, but the use of these therapies may be limited by the surgical accessibility of these tumors and their proximity to critical structures. The World Health Organization classification of pituitary neuroendocrine tumors was updated in 2022. Scientific advances have led to an enhanced understanding of the genetic drivers of many types of skull base tumors and have revealed several potentially targetable genetic alterations. This information is being leveraged in the design of ongoing clinical trials, with the hope of rendering these challenging tumors treatable through less invasive and morbid measures.

Essential Points
Tumors involving the skull base are heterogeneous and may arise from bony structures, cranial nerves, the meninges, the sinonasal tract, the pituitary gland, or embryonic tissues. Treatment often requires a multidisciplinary approach, with participation from radiation oncologists, medical oncologists, neuro-oncologists, and surgical specialists, including neurosurgeons, otolaryngologists, and head and neck surgeons. Treatment has largely centered around surgical resection, when feasible, and the use of first-line or salvage radiation therapy, with chemotherapy, targeted therapy, or both considered in selected settings. Our growing understanding of the molecular drivers of these diseases may facilitate future expansion of pharmacologic options to treat skull base tumors.
Retrosigmoid Intradural Suprameatal Approach: 2-Dimensional Operative Video
Authors: Samii Amir , Giordano Mario , Samii Madjid 
Published: December 2023

INDICATIONS: CORRIDOR AND LIMITS OF EXPOSURE:
The retrosigmoid intradural suprameatal approach is mostly indicated for tumors in the cerebellopontine angle extending toward the Meckel cave and supratentorial regions, most frequently meningiomas and schwannomas. This approach was first established by the senior author in 1982.

ANATOMIC ESSENTIALS: NEED FOR PREOPERATIVE PLANNING AND ASSESSMENT:
Nervous structures: cranial nerves III to XII, cerebellum, and brainstem. Vascular structures: anterior inferior cerebellar artery, posterior inferior cerebellar artery, superior cerebellar artery, basilar artery, vertebral artery, transverse, sigmoid, and petrous sinus, petrosal vein/veins, basilar plexus, and the mastoid emissary vein. Bony structures: petrous bone with internal auditory canal, jugular foramen and suprameatal tubercle, petrous apex, dorsum sellae, and posterior clinoid process. Structures within the petrous bone: vestibule, semicircular canals, and jugular bulb.

ESSENTIALS STEPS OF THE PROCEDURE:
After a suboccipital retrosigmoid craniectomy in the semisitting position and debulking of the tumor mass in the cerebellopontine angle, extension is achieved by drilling suprameatal tubercle above cranial nerve VII and VIII toward the petrous apex. The extent of bone drilling is tailored for each patient.

PITFALLS/AVOIDANCE OF COMPLICATIONS:
Avoid damage to cranial nerves, arteries, and veins during drilling, dissection, and tumor removal or by retraction.

VARIANTS AND INDICATIONS FOR THEIR USE:
In case of extreme supratentorial extensions laterally and dorsally, the opening of the tentorium may be helpful. For inferior extensions toward the upper spinal canal, opening of the foramen magnum and hemilaminectomy of C1 may be necessary.
The patient consented to the procedure and to the publication of his/her image. Institutional logo in title slide, © 2023, INI Hannover. Used with permission.
Upper Urinary Tract Urothelial Cancer After Radical Cystectomy for Bladder Cancer: Survival Outcomes After Radical Nephroureterectomy
Authors: Ślusarczyk Aleksander , Zapała Piotr , Piecha Tomasz , Zapała Łukasz , Borkowski Tomasz , Radziszewski Piotr 
Published: December 2023

Abstract
Background
Systemic and local recurrences of urothelial bladder cancer (UBC) significantly impair survival after radical cystectomy (RC), but little is known about the impact of the recurrence of urothelial cancer in the upper urinary tract (UTUC). This report describes survival outcomes and their predictors for patients who underwent RC followed by radical nephroureterectomy (RNU) for UTUC.

Methods
The Surveillance, Epidemiology, and End Results database was queried to identify patients who underwent RC for UBC and subsequent RNU for UTUC. The Kaplan–Meier method and competing-risk Cox regression (CRR) were used for the survival analysis.

Results
Overall, 102 patients have undergone RNU within a median of 49 months (interquartile range [IQR], 27–76 months) since RC. Muscle-invasive UTUCs were predominant at RNU (n = 58; 56.7%), but organ-confined bladder tumors were most frequent at RC (n = 42, 41.5%). After RNU, the estimated 5-year overall survival (OS) was 25.9%, the cancer-specific survival (CSS) was 35.6%, the median OS was 23 months (IQR, 11–63 months), and the CSS was 34 months (IQR, 13–132 months). In the multivariable CRR, the factors predictive for CSS after RNU included male gender (hazard ratio [HR], 2.36; 95% confidence interval [CI], 1.03–5.42; p < 0.05), muscle-invasive UTUC (HR, 2.20; 95% CI, 1.13–4.28; p < 0.05), and the presence of distant metastasis (HR,11.59; 95% CI, 5.33–25.2; p < 0.001).

Conclusions
In conclusion, the patients who underwent RNU for UTUC after RC for UBC experienced poor OS and CSS. The majority of RNUs were performed for locally advanced tumors. The independent risk factors for worse OS and CSS after RNU were UTUC T stage, presence of metastasis, and male gender.
CONSERVATIVE TREATMENT OF BREAST C YSTS: POSSIBILITIES OF USING INDINOLE FORTO
Authors: Guseynov Arif , Guseynov T. , Bobkov M. , Blincov V. 
Published: December 2023

Among the drugs used in the conservative therapy of breast cysts and fibrocystic mastopathy, phytopreparations are mainly used in clinical practice.
The drug Indinol Forto, obtained from plants of the cruciferous family, contains indolecarbinol, the effect of which is associated with the regulation of estrogen metabolism, inhibition of pathological proliferation, blockade of the formation of inflammatory cytokines, activation of apoptosis of transformed cells, reduction of breast cysts. The paper presents the results of a study of the pharmacological effect of the drug Indinol Forto on cystic formations of the breast. A comparative study of the use of the drug Indinol Forto showed its high effectiveness in the treatment of breast cysts, which consists in reducing the number and size of cystic formations of the breast. The drug Indinol Forto in the conservative treatment of breast cysts showed its effectiveness after 3 months of use: there was a decrease in the number of cysts (complete regression) by 3±0,5 in 13 (28,9%) patients and a partial regression of cysts with a decrease in their size by 28,7±5,8% in 16 (35,6%) patients. The optimal effect of Indinol Forto manifested itself after 6 months of use: the number of cysts decreased by 5±1,1 in 19 (42,2%) patients, and in 22 (48,9%) patients, a partial regression was noted with their reduction in size by almost half – by 49,0±7,2%. The results of the conducted studies have shown that Indinol Forto is the optimal drug that positively affects the dynamics of cystic formations of the breast. The drug Indinol Forto is well tolerated when taken orally, has no clinically identified side effects, which justifies the safety of long-term use.
Electric Vehicle Scheduling in Public Transit with Capacitated Charging Stations
Authors: de Vos Marelot H. , van Lieshout Rolf N. , Dollevoet Twan 
Published: December 2023

This paper considers the scheduling of electric vehicles in a public transit system. Our main innovation is that we take into account that charging stations have limited capacity, while also considering partial charging. To solve the problem, we expand a connection-based network in order to track the state of charge of vehicles and model recharging actions. We then formulate the electric vehicle scheduling problem as a path-based binary program, whose linear relaxation we solve using column generation. We find integer feasible solutions using two heuristics: price-and-branch and a diving heuristic, including acceleration strategies. We test the approach using data from the concession Gooi en Vechtstreek in the Netherlands, containing up to 816 trips. The diving heuristic outperforms the other heuristic and solves the entire concession within seven hours of computation time with an optimality gap of less than 3%. Supplemental Material: The online appendix is available at https://doi.org/10.1287/trsc.2022.0253 .
A Real-Time Control Policy to Achieve Maximum Throughput of an Online Order Fulfillment Network
Authors: Levin Michael 
Published: December 2023

Several major companies operate large online order fulfillment systems to ship goods from fulfillment centers through a distribution network to customer destinations in response to purchase orders. These networks make several types of decisions in real-time to serve customers. First, when a customer places an order, when and where (which fulfillment center) is it fulfilled from? Second, once an order has been packaged, how is it moved through the network to get to the customer? Making optimal decisions can yield significant cost savings or improvements in customer service. Unfortunately, these are large optimization problems, and are furthermore subject to uncertainty in the products and destinations of customer orders and the inventory replenishment of the fulfillment centers. This uncertainty makes the problem difficult to solve to optimality. Although the problem can be modeled as a Markov decision process, solving it exactly using standard computational methods is not possible due to the curse of dimensionality. We propose an alternative approach to this problem. We define a relatively simple real-time control policy and prove that it serves all customer demand if at all possible. This proof is achieved using Lyapunov drift techniques to relate the real-time control performance to the average performance necessary to serve all customers on average. Correspondingly, we characterize the average network performance, which may be used for network topology design while the control policy adapts to real-time stochasticity. We demonstrate the performance and stability properties on a numerical example based on hundreds of Amazon facility locations in the United States. The max-pressure control and greedy policies perform similarly at low demands, but at higher demand the throughput properties of the max-pressure control manifest as improvements in throughput and customer service metrics. Funding: Financial support from the National Science Foundation [Grant 1935514] is gratefully acknowledged. Supplemental Material: The e-companion is available at https://doi.org/10.1287/trsc.2023.0096 .
Changing faces: A case-based review of acromegaly
Authors: Mughal Rhyanna , Corsar K , Barker CS 
Published: December 2023

Acromegaly is a rare and underdiagnosed acquired disorder. It is commonly caused by an underlying pituitary adenoma that often requires surgical excision. Diagnosis is normally preceded by ~5–10 years of excessive growth owing to hypersecretion of growth hormone. This can have long-term medical complications and result in a reduced life expectancy. Acromegalic patients present to a number of healthcare professionals prior to diagnosis, including general dental practitioners. As changes in occlusion are often a patient's primary concern prior to acromegaly diagnosis, it is important that all dentists are aware of the presentation and differential diagnoses of such disorders.CPD/Clinical Relevance: Dentists should be aware of the initial presentation of acromegaly to facilitate early diagnosis.